about
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial.Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.Clinical outcomes with the STENTYS self-apposing coronary stent in patients presenting with ST-segment elevation myocardial infarction: two-year insights from the APPOSITION III (A Post-Market registry to assess the STENTYS self-exPanding COronary SDeterminants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: insights from the French FAST-MI program over 15 years.Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors.A puzzling electrocardiogram.Can we override clopidogrel resistance?Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: the FAST-MI registry.Thrombus composition in sudden cardiac death from acute myocardial infarction.Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study.Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial centerHeparin or enoxaparin anticoagulation for primary percutaneous coronary interventionPretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary SyndromesHigh on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET studyCYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post–Myocardial Infarction PatientsMicroparticles and sudden cardiac death due to coronary occlusion. The TIDE (Thrombus and Inflammation in sudden DEath) studyAltered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosisPrevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: the UGLA surveyOne-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stentOptimal use of thienopyridines in non-ST-elevation acute coronary syndrome following CURRENT-OASIS 7Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD StudyShort-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure. The AERER study[Myocardial infarction: Role of new antiplatelet agents]Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: The PEPCIT studyAnticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?Rapid P2Y12 inhibition: still an unmet medical need[Management of ST-elevation myocardial infarction in 2012]Bedside monitoring to adjust antiplatelet therapy for coronary stentingNew insights for low dosing with the new P2Y12 inhibitorsAmbulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of TicagrelorPrimary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians: a multicenter studyCorrigendum: new insights for low dosing with the new P2Y₁₂ inhibitors – lesson from the EastMeasuring and reversing the effect of non-vitamin K antagonist oral anticoagulants (NOACs)Impact of red blood cell transfusion on platelet aggregation and inflammatory response in anemic coronary and noncoronary patients: the TRANSFUSION-2 study (impact of transfusion of red blood cell on platelet activation and aggregation studied withIdentification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assayPrasugrel monitoring and bleeding in real world patients[Coronary stents: 30 years of medical progress]
P50
Q34910745-A70AE2A3-F63A-482F-9C91-DFE5936785FCQ35000773-974BF7A5-97C0-4FA0-8A47-16D8D29E95F2Q36244001-40CA8802-1E11-4912-9027-7E1DF93FB179Q38964426-EE46AFFE-0427-4042-B8F0-F1EA8E210DD9Q39077492-8C8BDCEF-6003-4102-AE84-1D2FD7FDE108Q43156282-642DC7AB-61BC-46B3-B025-16965C2D752FQ43904132-19C3B44E-45F8-4562-AC79-4AE1BBCF3DF8Q44423871-21C42F57-FAB7-4404-AE83-83C441F0FBC0Q44699596-5EEA7C2D-C964-4F33-936E-EABEAFF0FEB3Q45987163-E570B054-E85A-47DA-87F5-EA68C7BCFC34Q47297415-938E2427-5E0A-428C-8C7B-F32C5E220A58Q50455380-889FB5B1-15D0-4043-9C9E-830A154FFB3CQ51031250-F4B70ACF-B020-49A1-BCA8-98E738510354Q56837753-64A3744C-A98A-45D9-A12C-B4CF614B7906Q56837771-CE6F4D32-BFB1-4910-9668-B4726CD54954Q57914521-109E9A18-8BF9-47EC-A561-37DACA41FE7FQ60018122-D86911E7-600D-4F19-9A87-5EF5C93003EDQ60018251-5DEBB8BC-CAB9-4F16-9B6E-F8516069CD29Q60621566-D5AF6DA6-8838-48B1-979F-5041634C1996Q80134628-46047713-E168-4CA4-BA9E-70653F08A6B1Q82532986-E31C6698-0ABC-4886-9831-352E8BA47143Q82863155-D2B6C27B-A96A-4FC0-9F21-0A79CC4B8E1CQ83420451-FCF91E29-F1F9-49CE-BFE5-60C183F75039Q83660558-257D2F97-4A03-4243-BD0A-5ECB80FD4A36Q83907346-B5071412-F09D-4032-856A-C4AB40A7ED7AQ83928058-4503B9C3-C824-45F4-A022-775BFC5E3B09Q84208488-8E5C1DAD-AD22-4ED1-8820-C7E291568D57Q84400201-B85B6FBF-7F8D-4237-8891-C0D8A0BAAACEQ84417286-FCC2AA02-2407-4E30-AF64-0BC6FF2648BDQ85223596-142BF478-C85C-447A-B7AD-CE61D788D132Q85345517-4ED1B6FA-0875-478B-8CF9-01ACDE1E4623Q85952763-87390AEE-C9A8-4528-963B-40155F3D013EQ86503089-86F6333E-F555-4657-B5D7-1EFE31BE3084Q86752934-1A3703F8-B378-455D-A68F-7DC1ADCCF066Q86877003-9E7726C6-7932-4BF7-AFFB-1D1085627545Q86877220-D3C8241B-A399-4ED8-813C-9F112C697B28Q86990691-751C4720-04E1-4D90-9C69-D1085EE35922Q87217611-69C12CD8-1363-4944-BA97-27C82E9520CAQ87414259-3BC08202-9798-4B4A-A593-6F3F2FBDE236Q87566485-4F19BCE4-CC7A-4BC1-A009-04F98E6F0173
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Johanne Silvain
@ast
Johanne Silvain
@en
Johanne Silvain
@es
Johanne Silvain
@nl
type
label
Johanne Silvain
@ast
Johanne Silvain
@en
Johanne Silvain
@es
Johanne Silvain
@nl
prefLabel
Johanne Silvain
@ast
Johanne Silvain
@en
Johanne Silvain
@es
Johanne Silvain
@nl
P106
P31
P496
0000-0002-1901-2808